Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 15 January 2026

Sec. NK and Innate Lymphoid Cell Biology

Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1779800

Correction: Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks

This article is a correction to:

  1. Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks

    1. Read original article
Scott L. Baughan,*Scott L. Baughan1,2*Timothy Folsom,,Timothy Folsom2,3,4Matt Johnson,,Matt Johnson2,3,4Joshua Kreuger,,Joshua Kreuger2,3,4Beau R. Webber,,Beau R. Webber2,3,4Branden S. Moriarity,,Branden S. Moriarity2,3,4
  • 1Department of Medicine, University of Minnesota Twin Cities, Minneapolis, MN, United States
  • 2Center for Genome Engineering, University of Minnesota, Minneapolis, MN, United States
  • 3Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States
  • 4Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States

A Correction on
Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks

By Baughan SL, Folsom T, Johnson M, Kreuger J, Webber B and Moriarity BS (2025) Front. Immunol. 16:1704404. doi: 10.3389/fimmu.2025.1704404

The following Funding information was erroneously omitted: “Catamaran Bio, NIH grants R21CA237789, R21AI163731, P01CA254849, P50CA136393, R01AI146009, U54CA268069, Children’s Cancer Research Fund, Cure Childhood Cancer, the Randy Shaver Cancer Research and Community Fund to Beau R. Webber and Brandon S. Moriarity, and from Office of Discovery and Translation, NIH grants (R01AI146009, R01AI161017, P01CA254849, P50CA136393, U24OD026641, U54CA232561, P30CA077598, U54CA268069, DOD grants HT9425-24-1-1005, HT9425-24-1-1002, HT9425-24-1-0231), and Children’s Cancer Research Fund, the Fanconi Anemia Research Fund, and the Randy Shaver Cancer and Community Fund to Brandon S. Moriarity”.

The original version of this article has been updated.

Keywords: natural killer (NK) cells, chimeric antigen receptors (CARs), CAR-NK cells, IL-15 cytokine-armored CAR-NK, cytokine release syndrome, CAR-T cell therapy, cytokine release syndrome (CRS)

Citation: Baughan SL, Folsom T, Johnson M, Kreuger J, Webber BR and Moriarity BS (2026) Correction: Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks. Front. Immunol. 17:1779800. doi: 10.3389/fimmu.2026.1779800

Received: 02 January 2026; Accepted: 06 January 2026;
Published: 15 January 2026.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2026 Baughan, Folsom, Johnson, Kreuger, Webber and Moriarity. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Scott L. Baughan, YmF1Z2gwODZAdW1uLmVkdQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.